Evidence map›Paper›PMID 39855457›Full record

ArticleExperimental hematology2025

TET2-loss enhances immediate and time-resolved interferon-γ signaling responses across myeloid differentiation.

Matthew T Jenkins, Yunli E Chu, Alana M Franceski, Chad R Potts, Rebecca Dubin, Kirsten M Dickerson, Stanley C Lee, Rui Lu, Robert S Welner, P Brent Ferrell

Abstract read
In one paragraph

Article in Experimental hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Clonal Hematopoiesis of Indeterminate Potential Influences Breast Cancer Outcomes in a Genotype-Specific Manner.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Matthew T JenkinsDepartment of Pharmacology, Vanderbilt University, Nashville, TN; Department of Medicine, Division of Hematology/Oncology & Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN.
Yunli E ChuDepartment of Medicine, Division of Hematology/Oncology & Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN; Program in Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN.
Alana M FranceskiDivision of Hematology/Oncology and O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, Birmingham, AL.
Chad R PottsDepartment of Medicine, Division of Hematology/Oncology & Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN.
Rebecca DubinDepartment of Medicine, Division of Hematology/Oncology & Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN.
Kirsten M DickersonDepartment of Medicine, Division of Hematology/Oncology & Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN.
Stanley C LeeTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA.
Rui LuDivision of Hematology/Oncology and O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, Birmingham, AL.
Robert S WelnerDivision of Hematology/Oncology and O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, Birmingham, AL.
P Brent FerrellDepartment of Medicine, Division of Hematology/Oncology & Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN; Nashville Veterans Affairs Hospital, Tennessee Valley Health Care, Department of Veterans Affairs, Nashville, TN. Electronic address: brent.ferrell@vumc.org.

Funding

Transcriptional and epigenetic heterogeneity of stem/progenitor cellsP01HL131477 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI David T Scadden · 2017 to 2026
$24.6M
Medical Scientist Training ProgramT32GM152284 · NIGMS · VANDERBILT UNIVERSITY · PI Christopher S. Williams · 2024 to 2026
$4.8M
Causes and consequences of genomic instability in myelodysplasiaR01CA292932 · NCI · FRED HUTCHINSON CANCER CENTER · PI Stanley Chun-Wei Lee · 2024 to 2026
$2.7M
MEF2D-Mediated Transcriptional Control of Acute Myeloid LeukemiaR01CA259480 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Rui Lu · 2022 to 2026
$1.7M
Role of bone marrow Tregs in maintaining stromal cell functionR01HL150078 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WELNER, ROBERT S · 2020 to 2023
$1.5M
Investigating the role of the JAK/STAT3 Pathway in Clonal Proliferation and Immune Dysfunction in Myelodysplastic SyndromeK23HL138291 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI FERRELL, PAUL B · 2017 to 2021
$817k
Delineating Drivers of Inflammation and Progression in Clonal HematopoiesisR56DK138826 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI FERRELL, PAUL B · 2023 to 2023
$150k
BLRD VA I01 BX005991NCI NIH HHS R01 CA259480NCI NIH HHS R01 CA292932NHLBI NIH HHS K23 HL138291NHLBI NIH HHS P01 HL131477NHLBI NIH HHS R01 HL150078NIDDK NIH HHS R56 DK138826NIGMS NIH HHS T32 GM152284
6 · The paper itself

Abstract

Signaling responses to cytokines are disrupted in clonal hematopoiesis and myeloid malignancies. To better identify specific signaling response alterations in the presence or absence of TET2, we developed a 36-parameter cytometry by time-of-flight (CyTOF) panel of both surface marker and phosphoprotein antigens in murine bone marrow (BM). We show diverse, cell-type specific inflammatory cytokine responses in healthy hematopoietic cells. We next investigated changes associated with BM cells from Tet2

Indexed as

Cell DifferentiationDNA-Binding ProteinsInterferon-gammaProto-Oncogene ProteinsSignal TransductionAnimalsDioxygenasesHematopoietic Stem CellsJanus Kinase 2MiceMice, KnockoutSTAT1 Transcription FactorDioxygenasesDNA-Binding ProteinsInterferon-gammaJanus Kinase 2Proto-Oncogene ProteinsStat1 protein, mouseSTAT1 Transcription FactorTet2 protein, mouse

Identifiers

PMID39855457
PMCPMC12445325

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.